GSK Pharma to optimise product portfolio to drive growth in India Medical Dialogues Bureau24 Jun 2019 3:49 AM GMTGSK is also looking to launch some new products in the country over the next 15 months as it adopts a more structured approach to engage trade channel...
Cipla gets no USFDA observations for Indore facility Farhat Nasim18 May 2019 4:15 AM GMTThe US health regulator conducted a post-approval inspection at Cipla Ltd's Indore facility from 13th May to 17th May 2019. New Delhi: Drug firm Cipla...
AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise Medical Dialogues Bureau10 May 2019 3:30 AM GMTThe treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic...
Mylan launches Advair generic at 70 percent discount in US Farhat Nasim14 Feb 2019 3:45 AM GMTThe treatment, the first generic of Advair, is approved in three doses and will be priced between $93.71 and $153.14, the company said.U.S: Mylan NV...
GSK bets on pioneering cancer therapy with Adaptimmune deal Ruby Khatun Khatun9 Sep 2017 4:02 AM GMTLONDON: GlaxoSmithKline (GSK) said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology,...
